• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tigermed takes majority stake in Frontage Labs

Tigermed takes majority stake in Frontage Labs

May 13, 2014
CenterWatch Staff

Chinese CRO Hangzhou Tigermed Consulting, through its subsidiary Hong Kong Tigermed, will acquire a majority ownership position in Exton, Pa.-based Frontage Laboratories for $50.25 million in cash.  

Frontage provides services in bioanalysis, preclinical and early phase clinical studies, drug development (CMC) services and DMPK support. It offers services from discovery through late stage clinical trials for novel, generic and consumer product development programs. It also owns Frontage Lab (Shanghai). Tigermed currently has about 1,000 employees in over 50 locations in China and Asia Pacific. 

Frontage will continue to operate independently. Dr. Song Li will continue to serve as CEO, and its current management team will remain in place after the transaction.

“Tigermed is continuing to develop our capabilities to enhance our development solution offerings and help our customers reduce the time and cost of product development,” said Dr. Xiaoping Ye, founder and CEO of Tigermed. “We are achieving this goal through a strategic combination of our clinical development expertise and well-recognized technology service providers like Frontage.”

“Tigermed is the ideal fit for Frontage,” said Dr. Song Li, founder and CEO of Frontage Laboratories. “Frontage’s specialties in early phase development and CMC services are wholly complementary to Tigermed’s strengths in late phase clinical development in China and other Asia Pacific countries. This partnership enables Frontage to offer its existing clients a more comprehensive solution for clinical trial support, from phases I through IV. In turn, Tigermed’s clients will now have better access to early phase development solutions to facilitate efficient development programs.” 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing